1. Home
  2. INCY

INCY

Incyte Corp.

Logo Incyte Corp.

Health Care

Biotechnology: Commercial Physical & Biological Resarch

Nasdaq

as 04-19-2024 4:00pm EST

$
-
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.

Founded: 1991 Country:
United States
United States
Employees: N/A City: WILMINGTON
Market Cap: 11.9B IPO Year: 1993
Target Price: $75.31 AVG Volume (30 days): 1.7M
Analyst Decision: Buy Number of Analysts: 15
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: 2.65 EPS Growth: 74.34
52 Week Low/High: $50.27 - $75.74 Next Earning Date: 04-30-2024
Revenue: $3,695,649,000 Revenue Growth: 8.87%
Revenue Growth (this year): 14.51% Revenue Growth (next year): 10.73%

Share on Social Networks: